or
forgot password

Phase II Study of Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer


Phase 2
18 Years
N/A
Not Enrolling
Both
Head and Neck Cancer

Thank you

Trial Information

Phase II Study of Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer


Inclusion Criteria:



- Stage III, IV SCCHN

- Completed curative treatment

Exclusion Criteria:

- Prior chemotherapy or radiotherapy

- Recurrent disease

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

One year disease free

Outcome Time Frame:

1 year

Safety Issue:

No

Principal Investigator

Amy Law, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Geisinger Clinic

Authority:

United States: Institutional Review Board

Study ID:

2008-0153

NCT ID:

NCT00750555

Start Date:

September 2008

Completion Date:

December 2009

Related Keywords:

  • Head and Neck Cancer
  • squamous cell cancer of head and neck
  • SCCHN
  • Head and Neck Neoplasms

Name

Location
Geisinger Health System Wilkes Barre, Pennsylvania  18711